Sanne K Stuart1, Toon J L Kuypers1, Ingrid S Martijnse1, Joos Heisterkamp1, Robert A Matthijsen2. 1. Department of Surgery, Elisabeth-TweeSteden Hospital, Postbus 90151, 5000 LC , Tilburg, The Netherlands. 2. Department of Surgery, Elisabeth-TweeSteden Hospital, Postbus 90151, 5000 LC , Tilburg, The Netherlands. r.matthijsen@etz.nl.
Abstract
BACKGROUND: After esophagectomy for esophageal carcinoma, 2-13% of patients develop brain metastases (BM) which are associated with a poor prognosis. Further investigation into treatment and prognosis is beneficial given the limited available literature and varying outcomes. METHODS: Case files of all 339 patients who underwent minimally invasive esophagectomy (MIE) in a single high-volume center between January 2015 and December 2020 were retrospectively reviewed. Patients with BM and isolated brain metastases (iBM) were identified and a survival analysis was performed. RESULTS: Fifteen out of 339 patients (4,4%) undergoing MIE developed BM of which 9 (60,0%) had iBM. Most patients were diagnosed with squamous cell carcinoma (55,6%), localized in the middle third of the esophagus (66,7%), and had a pathologic complete response (66,7%) after initial treatment. Treatment of iBM consisted of gamma knife (GK) radiosurgery (44,4%), surgical resection (22,2%), GK and surgical resection (11,1%), and best supportive care (22,2%). Median time to diagnose iBM was 8,4 months (range 0,2-37,5) and survival after detection of iBM was 14,3 months (95% CI 0,0-45.9). The 2-year survival rate after detection of iBM was 44,4%. CONCLUSIONS: iBM after esophagectomy for esophageal carcinoma is rare, but when encountered can and should be treated with a curative intent in selected cases in close collaboration with large neurosurgical centers. A large-scale study should be conducted to confirm our findings.
BACKGROUND: After esophagectomy for esophageal carcinoma, 2-13% of patients develop brain metastases (BM) which are associated with a poor prognosis. Further investigation into treatment and prognosis is beneficial given the limited available literature and varying outcomes. METHODS: Case files of all 339 patients who underwent minimally invasive esophagectomy (MIE) in a single high-volume center between January 2015 and December 2020 were retrospectively reviewed. Patients with BM and isolated brain metastases (iBM) were identified and a survival analysis was performed. RESULTS: Fifteen out of 339 patients (4,4%) undergoing MIE developed BM of which 9 (60,0%) had iBM. Most patients were diagnosed with squamous cell carcinoma (55,6%), localized in the middle third of the esophagus (66,7%), and had a pathologic complete response (66,7%) after initial treatment. Treatment of iBM consisted of gamma knife (GK) radiosurgery (44,4%), surgical resection (22,2%), GK and surgical resection (11,1%), and best supportive care (22,2%). Median time to diagnose iBM was 8,4 months (range 0,2-37,5) and survival after detection of iBM was 14,3 months (95% CI 0,0-45.9). The 2-year survival rate after detection of iBM was 44,4%. CONCLUSIONS: iBM after esophagectomy for esophageal carcinoma is rare, but when encountered can and should be treated with a curative intent in selected cases in close collaboration with large neurosurgical centers. A large-scale study should be conducted to confirm our findings.
Authors: Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: M van Putten; J de Vos-Geelen; G A P Nieuwenhuijzen; P D Siersema; V E P P Lemmens; C Rosman; M J C van der Sangen; R H A Verhoeven Journal: Eur J Cancer Date: 2018-03-20 Impact factor: 9.162
Authors: Kazuto Harada; Hyunsoo Hwang; Xuemei Wang; Ahmed Abdelhakeem; Masaaki Iwatsuki; Mariela A Blum Murphy; Dipen M Maru; Brian Weston; Jeffrey H Lee; Jane E Rogers; Allison Trail; Namita Shanbhag; Meina Zhao; Manoop S Bhutani; Quynh-Nhu Nguyen; Stephen G Swisher; Naruhiko Ikoma; Prajnan Das; Wayne L Hofstetter; Brian D Badgwell; Jaffer A Ajani Journal: Gastric Cancer Date: 2020-04-28 Impact factor: 7.370
Authors: B P Müller-Stich; P Probst; H Nienhüser; S Fazeli; J Senft; E Kalkum; P Heger; R Warschkow; F Nickel; A T Billeter; P P Grimminger; C Gutschow; T S Dabakuyo-Yonli; G Piessen; M Paireder; S F Schoppmann; D L van der Peet; M A Cuesta; P van der Sluis; R van Hillegersberg; A H Hölscher; M K Diener; T Schmidt Journal: Br J Surg Date: 2021-09-27 Impact factor: 6.939
Authors: Robert A Meguid; Craig M Hooker; Joshua T Taylor; Laurence R Kleinberg; Stephen M Cattaneo; Marc S Sussman; Stephen C Yang; Richard F Heitmiller; Arlene A Forastiere; Malcolm V Brock Journal: J Thorac Cardiovasc Surg Date: 2009-12 Impact factor: 5.209
Authors: Alicia S Borggreve; B Feike Kingma; Serg A Domrachev; Mikhail A Koshkin; Jelle P Ruurda; Richard van Hillegersberg; Flavio R Takeda; Lucas Goense Journal: Ann N Y Acad Sci Date: 2018-05-15 Impact factor: 5.691
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702